Immuneering Corp

Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Immuneering Corp advances oncology focus with promising preclinical data

Immuneering Corp (IMRX) is making significant strides in oncology with promising preclinical data and a strategic focus on developing cancer treatments with better tolerability.
While facing challenges in addressing resistance and clarifying MEK inhibitor activity, the company's unique approach and strong response profiles position them well for future growth.
Opportunities lie in advancing pipeline assets, optimizing clinical trial outcomes through informatics, and leveraging expertise in relevant cancer types for Phase 2a success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Cowen 44th Annual Health Care Conference, which is taking place at the Marriott Copley Place in Boston from March 4-6, 2024, to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Brett Hall, Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, Chief Accounting Officer, Treasurer.

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

- Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 - - Dosing of first patient in the expanded Phase 2a portion of Phase 1/2a trial of IMM-1-104 expected in March 2024; initial data from multiple arms expected in 2024 - - FDA Fast Track designation received for IMM-1-104 in pancreatic cancer - - Dosing of first patient in the Phase 1/2a trial of IMM-6-415 expected in March 2024 - - Cash runway into 2H 2025 - CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business updates.

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

– Fast Track designation has the potential to accelerate lead asset IMM-1-104's path to U.S. FDA submission for pancreatic ductal adenocarcinoma –

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Vir Biotechnology

VistaGen Therapeutics

The global biotechnology market is a treasure trove of hidden-gem biotech stocks. Valued at $1.55 trillion in 2023, it is anticipated to grow at a CAGR of 13.96% from 2024 to 2030.

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in two February investor conferences to discuss the company's pipeline, platform and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

Immuneering Announces Participation in February Investor Conferences

- Dosing of first patient in the Phase 1/2a clinical trial expected in early 2024 - CAMBRIDGE, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IMM-6-415, paving the way for the company to initiate a Phase 1/2a clinical trial of this oral, twice-daily small molecule, in development for the treatment of advanced RAF or RAS mutant solid tumors.

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 35th Annual Piper Sandler Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

-Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering's recommendation for a Phase 2 dose expected in early 2024 -

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven tumor types, including models of RAS and RAF mutant melanoma, pancreatic cancer, and lung cancer

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it will present preclinical data on IMM-1-104, its lead clinical-stage program, and IMM-6-415 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston.

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Morgan Stanley Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Chief Accounting Officer and Treasurer.

Immuneering to Present at the Morgan Stanley Healthcare Conference

- Positive initial pharmacokinetic, pharmacodynamic and safety data presented at American Association for Cancer Research (AACR) annual meeting, with IMM-1-104 demonstrating Cmax, half-life, and pERK/pMEK suppression consistent with deep cyclic inhibition of the MAPK pathway -

Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates

IMRX is an early-stage company with promising science. They do not have clinical efficacy data. While I like the company, be warned that this is going to take time.

Immuneering Corp.: Early Stage Promise, But Long-Term Investment

The average of price targets set by Wall Street analysts indicates a potential upside of 103.8% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet

- No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during the Phase 1a dose escalation portion of ongoing clinical study -

Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors

CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Jefferies Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.

Immuneering to Present at the Jefferies Healthcare Conference

Immuneering Corporation (IMRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.49 per share a year ago.

Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates

- Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting -

Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX) (“Immuneering”), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced the pricing of its underwritten offering of 2,727,273 shares of its Class A common stock at an offering price of $11.00 per share. The gross proceeds from the offering are expected be $30 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering. All shares in the offering will be offered by Immuneering.

Immuneering Announces $30 Million Underwritten Offering

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, announced positive initial pharmacokinetic (PK), pharmacodynamic (PD) and safety data from the Phase 1 trial of IMM-1-104 (NCT05585320), which are being shared today in a poster presentation titled “Humanized 3D tumor models that are mutationally aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors” (abstract #4265) at the American Association for Cancer Research (AACR) annual meeting.

Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline

CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.

Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

Immuneering Corporation (IMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?

- Investor call to be held at 9:00 a.m. ET on April 18, 2023 - - Investor call to be held at 9:00 a.m. ET on April 18, 2023 -

Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise

Immuneering Appoints Harold E. Brakewood as Chief Business Officer

The average of price targets set by Wall Street analysts indicates a potential upside of 102.5% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

News for Immuneering Corp Stock (IMRX)